Key facts
- This page summarizes Rick E. Winningham's Form 4 filing for Jazz Pharmaceuticals plc (JAZZ).
- 2 reported transactions and 0 derivative rows are listed below.
- Accepted by SEC: 09 Aug 2022, 18:52.
Rick E. Winningham - 05 Aug 2022 Form 4 Insider Report for Jazz Pharmaceuticals plc (JAZZ)
- Reporting relationship
- Director
- Issuer ticker
- JAZZ
- Reported as of
- 05 Aug 2022
- Net transaction value
- -$165,879
- SEC form
- 4
- Accepted by SEC
- 09 Aug 2022, 18:52:46 UTC
- Prior SEC filing
- 24 May 2022
- Next SEC filing
- 23 Aug 2022
- Source filing
- View source filing
- Reporting owner signature
- By: /s/Adam Guttmann, as attorney in fact For: Rick E Winningham
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Rick E. Winningham filed Form 4 for Jazz Pharmaceuticals plc (JAZZ) on 09 Aug 2022.
Change
- Previous filing in this sequence was filed on 24 May 2022.
- Current net transaction value: -$165,879.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
JAZZ
transaction
Ordinary Shares
Award
- Transaction value
- $0
- Shares
- +2,561
- Change %
- +36%
- Price
- $0.000000
- Shares after
- 9,699
- Date
- 05 Aug 2022
- Ownership
- Direct
- Footnotes
- F1
JAZZ
transaction
Ordinary Shares
Sale
- Transaction value
- $165,879
- Shares
- -1,089
- Change %
- -11%
- Price
- $152.32
- Shares after
- 8,610
- Date
- 08 Aug 2022
- Ownership
- Direct
- Footnotes
- F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
These restricted stock units are granted pursuant to the Issuer's 2007 Amended and Restated Non-Employee Directors Stock Award Plan. Each restricted stock unit represents a contingent right to receive one ordinary share upon the vesting of the unit. Subject to the Reporting Person's continuous service and certain additional conditions, these units will vest in full on July 28, 2023.
Footnote F2
Shares sold to satisfy tax obligations arising out of the vesting of previously granted restricted stock units.